The Zacks Analyst Blog Highlights Johnson & Johnson, Caterpillar, Qualcomm, Fossil and Jones Soda
Johnson & Johnson is gaining momentum as innovative medicines and a strengthening MedTech business support growth despite key patent headwinds.
Zacks·19d ago
More News
Top Analyst Reports for Johnson & Johnson, Caterpillar and Qualcomm
JNJ is leaning on Innovative Medicine growth and MedTech momentum to offset the Stelara patent cliff as it heads into 2026.
Zacks·19d ago
2 Microcaps Stacking the C-suite
AMNF and JSDA are two microcaps adding industry veterans to the C-suite.
Zacks·19d ago
Jones Soda's Q3 Revenues Rise as Loss Narrows, Outlook Improves
JSDA posts stronger Q3 results with higher revenues, lower losses and improving margins, while management outlines growth plans across core and new product lines.
Zacks·2mo ago
JSDA Posts Q2 Profit From Cannabis Sale Despite Y/Y Revenue Dip
Jones Soda posts Q2 profit from cannabis sale despite a y/y revenue drop, with product launches and retail expansion aimed at fueling growth.
Zacks·5mo ago
Jones Soda Q1 Loss Narrows Y/Y, Expenses Reduce, Revenues Fall 7.8%